Publication
Interfacial lipid digestion-responsive injectable nanoemulsions enhance lapatinib efficacy in triple-negative breast cancer.
Nidhi Singh, Satyajit Halder, Alok Kumar, Rudra Chakravarti, Anubroto Pal, Dipanjan Ghosh, Pravat Kumar Parida, Anup Kumar Misra, Somendu Kumar Roy, Kuladip Jana, Pallab Datta
- Source
- PubMed
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260910-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Lapatinib (LPT), a brick-dust kinase inhibitor, shows slow oral bioavailability and dose-limiting gastrointestinal side effects that frequently lead to therapeutic discontinuation. Increasing oral bioavailability does not mitigate these adverse effects, and developing complex LPT delivery systems…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Breast Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available